Personalized Closed-Loop Brain Stimulation for Patients With Mild Cognitive Impairment
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 10 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Active tES
- Cognitive Interventions
- Record updated
- 7 October 2026
Who can take part
- Age
- 45 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Must be between 45-85 years of age
- Must be proficient in English
- Must have a minimum of high-school education
- Must be diagnosed with 'probable Alzheimer's Disease (AD)' in specialized diagnostic centers with neuropsychological (e.g., RAVLT) and AD biomarkers according to 2011 guidelines
- The investigators will also perform extensive testing in the investigators' test battery including the Mnemonic Similarity Test (MST) that discriminates and measures the most salient hippocampal deficit-pattern separation (PS)
Who cannot take part
- People with previous neurological disease including vascular dementia (e.g., stroke, developmental dyslexia, dysgraphia or attentional deficit)
- People with advanced dementia or severe language impairments (MMSE <15, or Montreal Cognitive Assessment <10, or language Frontotemporal Dementia-specific Clinical Dementia Rating (FTD-CDR) =3)
- People with pre-existing psychiatric disorders such as behavioral disturbances, severe depression, or schizophrenia that do not allow these people to comply or follow the study schedule and requirements such as repeated evaluation and therapy
- People with hearing loss (> 25 decibel, using audiometric hearing screen)
- People with uncorrected visual acuity loss
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 85 years old?
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesContact: Kyrana Tsapkini, PhDNot yet recruiting
About the trial
What the trial wants to find out
This research study investigates the feasibility and efficacy of a personalized, closed-loop electroencephalogram-transcranial electrical stimulation (EEG-tES) intervention for individuals with mild cognitive impairment (MCI), addressing the inconsistent results of generic brain stimulation protocols. By integrating artificial intelligence (AI)-derived insights with real-time data, the study aims to customize transcranial electrical stimulation (tES) parameters, including electrode placement, intensity, and frequency to target the specific brain regions responsible for abnormal signaling in each participant. Over the intervention period paired with computerized cognitive training, the project will evaluate improvements in learning, memory, and functional connectivity, while simultaneously identifying clinical and physiological predictors to determine the viability of transitioning this low-cost, non-invasive technology into a remotely supervised, home-based therapy setting. The study duration will be a total of 6-8 weeks.
The group in the trial
- Personalized closed-loop tES treatment + Cognitive InterventionsTreatment being tested
Participants will receive personalized, closed-loop active tES for 3 weeks. Active tES will be administered for 20 minutes. Cognitive training exercises will be administered concurrently with the tES and will take approximately 30 minutes to complete.
Treatment: Active tES and Cognitive Interventions
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT07512193, who can take part
- Record updated
- 7 October 2026